Customize your JAMA Network experience by selecting one or more topics from the list below.
In the article titled “Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis,”1 published in the February 2022 issue, there was a transcription error in the IQR of the median time of treatment with edaravone in the Results section of the Abstract and text and transcription errors in the data in the follow-up section of Table 1. This article was corrected online.
Errors in Results in Abstract and Text and in Table 1. JAMA Neurol. 2022;79(7):727. doi:10.1001/jamaneurol.2022.1581
Artificial Intelligence Resource Center